MedTrace Logo

A Rollover Study for Subjects Who Completed Participation in IMSA101-101 Trial

NCT06026254 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 2

Last updated 2024-11-18

No results posted yet for this study

Summary

This is a rollover study from parent protocol IMSA101-101 for adult patients with advanced malignancies that were previously receiving IMSA101 and who would continue to receive benefit with study treatment of IMSA101 in combination with an immune checkpoint inhibitor (ICI).

Conditions

  • Solid Tumor, Adult

Interventions

DRUG

IMSA101

Intra-tumoral administration on Days 1 and 15 of every 28-day cycle

DRUG

Immune Checkpoint Inhibitor

Administered according to product label

Sponsors & Collaborators

  • ImmuneSensor Therapeutics Inc.

    lead INDUSTRY

Principal Investigators

  • Teresa Mooneyham · ImmuneSensor Therapeutics

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-09-15
Primary Completion
2025-09-30
Completion
2025-09-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06026254 on ClinicalTrials.gov